SEATTLE, WA--(Marketwired - Feb 17, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Care Company, will exhibit at two upcoming medical conferences:

  • The 8th Annual International Symposium on the Breast: Using Next Generation Science to Understand the Normal Breast and the Development of Breast Cancer. This conference will be held in Santa Monica, California February 19-21, 2015. 

  • The National Consortium of Breast Centers Meeting to be held March 14-18, 2015 in Las Vegas, Nevada. This conference will include the FullCYTE Breast Aspirator device, which is used to collect nipple aspirate fluid for cytological analysis at a laboratory.

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "The 8th Annual International Symposium on the Breast is a key meeting as leaders from many regions in the field of breast health will come together to discuss breast health innovations regarding procedures and the latest developments." Dr. Quay continued, "The National Consortium of Breast Centers Meeting provides an important opportunity to meet with clinicians on breast health products, and we are looking forward to participating."

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health, Inc. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.